154 related articles for article (PubMed ID: 8336526)
1. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.
Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G
Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526
[TBL] [Abstract][Full Text] [Related]
2. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.
Milella M; Antonelli G; Santantonio T; Giannelli G; Currenti M; Monno L; Turriziani O; Pastore G; Dianzani F
Hepatogastroenterology; 1995 Jul; 42(3):201-4. PubMed ID: 7590565
[TBL] [Abstract][Full Text] [Related]
3. [The influence of anti-interferon-alpha 2a antibodies in initial daily four-week interferon-alpha 2a therapy for chronic hepatitis C].
Habu D; Mizuno M; Ohnishi K; Watanabe A; Son J; Iwano M; Murakoshi R; Takino T; Mizuma Y; Kobayashi M
Nihon Shokakibyo Gakkai Zasshi; 1997 May; 94(5):319-27. PubMed ID: 9170879
[TBL] [Abstract][Full Text] [Related]
4. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Del Vecchio S; Riva E; Broccia C; Schiraldi O; Dianzani F
Clin Exp Immunol; 1994 Jul; 97(1):4-9. PubMed ID: 8033418
[TBL] [Abstract][Full Text] [Related]
5. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha.
Bonetti P; Diodati G; Drago C; Casarin C; Scaccabarozzi S; Realdi G; Ruol A; Alberti A
J Hepatol; 1994 Mar; 20(3):416-20. PubMed ID: 7516951
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs.
Makris M; Preston FE; Triger DR; Underwood JC; Westlake L; Adelman MI
Blood; 1991 Oct; 78(7):1672-7. PubMed ID: 1912556
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
Douglas DD; Rakela J; Lin HJ; Hollinger FB; Taswell HF; Czaja AJ; Gross JB; Anderson ML; Parent K; Fleming CR
Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
11. Autoimmunity during alpha-interferon therapy for chronic hepatitis C.
Yoshikawa M; Sakamoto T; Mitoro A; Mochi T; Tsujii H; Koizumi M; Yoshiji H; Sakaguchi Y; Fukui H; Nakano H
Gastroenterol Jpn; 1993 May; 28 Suppl 5():109-14. PubMed ID: 8359620
[TBL] [Abstract][Full Text] [Related]
12. Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?
Puppo F; Picciotto A; Brenci S; Varagona G; Scudeletti M; Ghio M; Balestra V; Celle G; Indiveri F
J Clin Immunol; 1995 Jul; 15(4):179-84. PubMed ID: 7593464
[TBL] [Abstract][Full Text] [Related]
13. The quantitative humoral immune response to the hepatitis C virus is correlated with disease activity and response to interferon-alpha.
Löhr HF; Elste C; Dienes HP; Michel G; Braun HB; Meyer zum Büschenfelde KH; Gerken G
J Hepatol; 1996 Sep; 25(3):292-300. PubMed ID: 8895007
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
Prümmer O
Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy.
Antonelli G; Giannelli G; Currenti M; Simeoni E; Del Vecchio S; Maggi F; Pistello M; Roffi L; Pastore G; Chemello L; Dianzani F
Clin Exp Immunol; 1996 Jun; 104(3):384-7. PubMed ID: 9099919
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha 2-b therapy of HCV and nonBnonC chronic hepatitis.
Gargiulo M; Tarquini P; Di Ottavio L; Lattanzi E; De Nigris-Urbani A
Arch Virol Suppl; 1992; 4():304-5. PubMed ID: 1450709
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha.
Carreño V; Tapia L; Ryff JC; Quiroga JA; Castillo I
J Med Virol; 1992 Jul; 37(3):215-9. PubMed ID: 1331310
[TBL] [Abstract][Full Text] [Related]
19. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection.
Lok AS; Lai CL; Leung EK
Hepatology; 1990 Dec; 12(6):1266-70. PubMed ID: 2258142
[TBL] [Abstract][Full Text] [Related]
20. Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan.
Hou C; Chuang WL; Yu ML; Dai CY; Chen SC; Lin ZY; Hsieh MY; Wang LY; Tsai JF; Chang WY
Scand J Gastroenterol; 2000 Dec; 35(12):1288-93. PubMed ID: 11199369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
